Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody

Clinical and Experimental Dermatology

Volumn 30, Issue 1, 2005, Pages 46-48

  Lacouture, M E ^a   Baron, J M ^a   Jani, A B ^a   Laumann, A E ^a   Soltani, K ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; DIPHENHYDRAMINE; HYDROCORTISONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; PARACETAMOL; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; ARTICLE; B CELL LYMPHOMA; CANCER RECURRENCE; CANCER RELAPSE; CASE REPORT; CUTANEOUS B CELL LYMPHOMA; CYTOPENIA; DRUG EFFICACY; DRUG TOLERABILITY; HEART ARRHYTHMIA; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPOTENSION; LEG; MALE; MOUTH LESION; PAPULE; PRIORITY JOURNAL; SKIN LYMPHOMA; SKIN NODULE; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETREATMENT; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 13244287801     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2004.01659.x     Document Type: Article

References (7)

1. Willemze R, Kerl H, Sterry W, Berti E et al. EORTC Classification for Primary Cutaneous Lymphomas: a Proposal From the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90: 354-71.
2. Fung MA, Murphy MJ, Hoss DM, Grant-Kels JM. Practical evaluation and management of cutaneous lymphoma. J Am Acad Dermatol 2002; 46: 325-57.
3. Massengale WT, McBurney E, Gurtler J. CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy. J Am Acad Dermatol 2002; 46: 441-3.
4. Heinzerling LM, Urbanek M, Funk JO et al. Reduction of tumor burden and stabilization of disease by systemic therapy with Anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer 2000; 89: 1835-44.
5. Maloney DG, Smith B, Appelbaum FR. The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines [abstract]. Blood 1996; 88: 637a.
6. Tedder TF, Engel P. CD20. a regulator of cell cycle progression of B-lymphocytes. Immunol Today 1994; 91: 1644-52.
7. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003: 14: 520-35.